Ivax merges with distributor and extends licence to Glaxo
This article was originally published in Clinica
Executive Summary
Ivax, US manufacturer of generic pharmaceuticals, plans to merge with US distributor Bergen Brunswig. The merger has been approved by both companies' boards. A new company, BBI Healthcare, will be set up which will acquire both Bergen Brunswig and Ivax in stock swaps. The shareholders of Bergen Brunswig will end up with 56% of BBI Healthcare and Ivax shareholders with the rest.